Pharming has received acceptance from both the EMA and FDA for the accelerated review of leniolisib. The new drug is anticipated to generate significantly more revenue compared to its current profitable drug Ruconest. While the company has been profitable for the past years, it needed to find new sources of income to be able to grow the value of the company. The...
SHELL seems to lose long-term price support. If loss of support is confirmed, we could go back to 22-23 euro.
Top is to be discussed, also the slope could be steeper up.